Lenvima® (lenvatinib) Phase III Data in Advanced Thyroid Cancer: Live Virtual Press Event From the 15th International Thyroid Congress (ITC) 2015, Florida

HATFIELD, England, October 15, 2015 /PRNewswire/ --

- INVITATION FOR EUROPEAN AND ASIAN 

JOURNALISTS ONLY - 

MONDAY 19 OCTOBER 2015 @ 10:00–11:00 (EDT)

There is a major need for improved treatment options for radioiodine refractory differentiated thyroid cancer, an aggressive, difficult-to-treat cancer with poor prognosis and 10-year survival rates of only 15%.

This virtual press event will give you the opportunity to hear about the key role of lenvatinib in thyroid cancer from two experts in the field and give you exclusive access to them for direct questions and one-to-one interviews.

Professor Martin Schlumberger, University Paris Sud, France, will provide an overview of the key Lenvatinib Phase III data at ITC and focus on the effect of lenvatinib across different metastatic sites.

Dr Rosella Elisei, Department of Endocrinology and Metabolism, Section of Endocrinology, University of Pisa, Italy, will provide an overview of the SELECT trial including key results and trial design.

TO REGISTER PLEASE EMAIL TONIC.EISAI@TONICLC.COM  

If you would like to book an interview with one of the speakers after the press conference (either in person if you are onsite, or by telephone) please contact Callum Haire at Tonic Life Communications, Callum.Haire@toniclc.com / +44(0)20-7798-1036   

Eisai will be presenting seven abstracts at this year's ITC meeting which can be found below:

   
    Product                      Abstract Name          Session

                                                        Presentation
                                                        Short Oral
                                                        Communications Session
                                                        Date: Monday, October
    Outcomes by site of                                 19, 2015 from 16:30 PM
    metastasis for patients with                        - 17:30 PM
    radioiodine-refractory                              Poster:
    differentiated thyroid                              Monday, October 19 from
    cancer treated with                                 9:20 AM - 9:45 AM and
    lenvatinib versus placebo:                          3:05 PM- 4:00 PM
    results from a phase 3,      Habra MA, Song J,      Tuesday, October 20
    randomized trial             Rietschel P            from 9:20 AM - 9:45 AM


                                                        Monday, October 19 from
                                                        9:20 AM - 9:45 AM and
                                                        3:05 PM- 4:00 PM
    A Study of the Quality of    Hudgens S, Pelletier   Tuesday, October 20
    Survival In Radioiodine      C, Forsythe A, Taylor  from 9:20 AM - 9:45 AM
    Refractory Thyroid Cancer    M                      .                                                      
                                                       
    Incidence and Timing of      Haddad R, Schlumberger
    Common Adverse Events in     M, Wirth L, Sherman E, Wednesday, October 21
    Lenvatinib-treated Patients  Shah M, Robinson B,    from 9:20 AM - 9:45 AM
    With Radioiodine-refractory  Dutcus C, Teng A,      and 3:05 PM- 4:00 PM
    Thyroid Cancer From the      Gianoukakis A, Sherman Thursday, October 22
    SELECT Trial                 S                      from 9:20 AM - 10:20 AM
                                                       
    Lenvatinib and the effect of                       
    age on overall survival for                         Wednesday, October 21
    patients with                                       from 9:20 AM - 9:45 AM
    radioiodine-refractory                              and 3:05 PM - 4:00 PM
    differentiated thyroid       Brose M, Teng A,       Thursday, October 22
    cancer                       Rietschel P, Habra MA  from 9:20 AM - 10:20 AM
                                                       
    Efficacy and Safety of                             
    Lenvatinib by Body Mass      Tahara M, Wirth L,     Wednesday, October 21
    Index in Patients With       Brose M, Newbold K,    from 9:20 AM - 9:45 AM
    131I-refractory              Schlumberger M, Ductus and 3:05 PM- 4:00 PM
    Differentiated Thyroid       C, Robinson B,         Thursday, October 22
    Cancer                       Gianoukakis AG         from 9:20 AM - 10:20 AM
                                  
    Number Needed to Treat (NNT)                      
    Analysis of Therapies In                            Wednesday, October 21
    Radioiodine-Refractory                              from 9:20 AM - 9:45 AM
    Differentiated Thyroid                              and 3:05 PM - 4:00 PM
    Cancer (RAI-R DTC) Using     Tremblay G, Li X,      Thursday, October 22
    Indirect Comparison          Abouzaid S             from 9:20 AM - 10:20 AM
                                                     
    Characteristics of Patients                         Wednesday, October 21
    on Lenvatinib With                                  from 9:20 AM - 9:45 AM
    Treatment-emergent                                  and 3:05 PM- 4:00 PM
    Hypertension in the SELECT   Abouzaid S, Li X,      Thursday, October 22
    Trial                        Rietschel P            from 9:20 AM - 10:20 AM

TO REGISTER PLEASE EMAIL TONIC.EISAI@TONICLC.COM  

If you would like to book an interview with one of the speakers after the press conference (either in person if you are onsite, or by telephone) please contact Callum Haire at Tonic Life Communications, Callum.Haire@toniclc.com / +44(0)20-7798-1036    

This is not an official event at ITC 2015.

This event is not sponsored or endorsed by ITC or the American Thyroid Association.

Date of preparation: October 2015
Job code: Oncology-UK0063